Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DMT
- Development stage
- Phase 2
- Lead developer
- Small Pharma
- Modality
- Small Molecules
- Administration
- Intravenous, Inhalation, Oral
01
Overview
DMT (N,N-Dimethyltryptamine) is a naturally occurring psychedelic compound found in various plants, animals, and endogenously in humans. It is known for producing intense but relatively short-lived hallucinogenic effects. DMT is being investigated for its therapeutic potential, particularly in the treatment of major depressive disorder (MDD) and treatment-resistant depression (TRD), as well as anxiety and cluster headaches. Its mechanism of action primarily involves agonism of several serotonin receptors, notably 5-HT2A, 5-HT1A, and 5-HT2C, which are believed to mediate its psychedelic and therapeutic effects. It also interacts with serotonin, dopamine, and norepinephrine transporters, and has been shown to modulate other systems including glutamate and sigma-1 receptors, contributing to its neuroplasticity-promoting effects.
- Other names
- N,N-Dimethyltryptamine
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)TAAR1 (Trace amine-associated receptor 1)5-HT2 (5-HT2 receptor family)
Beyond the preview
Go deeper on DMT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DMT.